Who Paid My Doc
Erica Rabold
Critical Care Medicine Monroe, NC Medical Doctor
NPI 1164805925 CMS profile 5706291
1550 Faulk St, Ste 3120, Monroe, NC 28112
General payments
$5,258
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Erica Rabold of Monroe, NC is reported in the CMS Open Payments database as having received $5,258 across 30 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 86th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43 | 2 | |
| 2024 | General | $1,201 | 12 | |
| 2023 | General | $44 | 2 | |
| 2022 | General | $107 | 5 | |
| 2021 | General | $152 | 3 | |
| 2020 | General | $3,441 | 3 | |
| 2019 | General | $268 | 3 |
Beside peers
- Erica Rabold
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Erica Rabold were reported at $43. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Erica Rabold | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $268 | $149 | $51–$535 | $163 |
| 2020 | $3,441 | $110 | $30–$325 | $114 |
| 2021 | $152 | $125 | $34–$403 | $132 |
| 2022 | $107 | $157 | $49–$582 | $149 |
| 2023 | $44 | $162 | $56–$621 | $160 |
| 2024 | $1,201 | $168 | $53–$634 | $164 |
| 2025 | $43 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 37 drugsPart D claims
2,866
Drug cost
$1,525,865
Branded share of claims
73.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | Brand | 63 | $751,346 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 340 | $249,199 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 142 | $93,990 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 121 | $74,415 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 131 | $61,394 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 129 | $59,242 | |
| Pirfenidone | Generic | 19 | $41,168 | |
| Dupixent Pen Dupilumab | Brand | 11 | $39,325 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 42 | $35,307 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 696 | $17,068 |
The 10 drugs with the highest cost, of 37 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$108,490
Medicare patients
396
Services billed
1,447
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 51% | |
| Arthritis | 46% | |
| Ischemic heart disease | 43% | |
| Heart failure | 36% | |
| Diabetes | 35% | |
| Atrial fibrillation | 34% | |
| Chronic kidney disease | 34% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in North Carolina
Alexis Smith
Critical Care Medicine · Huntersville, NC
Rabih Bechara
Critical Care Medicine · Charlotte, NC
Alan Heffner
Critical Care Medicine · Charlotte, NC
Daniel Feinstein
Critical Care Medicine · Pinehurst, NC
Daniel Fox
Critical Care Medicine · Raleigh, NC
Hassan Yousaf
Critical Care Medicine · Winston Salem, NC
Related records
Critical Care Medicine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.